Stock Events

Stock Events

Oncopeptides AB (publ) 

$0.2650
29
-$0.64-70.56% Monday 20:00

Statistics

Day High
0.265
Day Low
0.265
52W High
0.265
52W Low
0.265
Volume
200
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.03
-0.03
-0.02
-0.02
Expected EPS
N/A
Actual EPS
N/A

Financials

-454.95%Profit Margin
Profitable
2018
2019
2020
2021
2022
2023
-195,034.9Revenue
887,311.29Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb competes in the oncology space with a broad portfolio of drugs that could be used in similar indications as Oncopeptides' therapies.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its subsidiary Janssen, develops multiple myeloma treatments that directly compete with Oncopeptides' products.
AMGEN
AMGN
Mkt Cap236.38B
Amgen has a strong presence in the oncology market, including treatments for multiple myeloma, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, with its acquisition of Kite Pharma, has expanded its oncology portfolio, including therapies that could compete in the same space as Oncopeptides.
Novartis
NVS
Mkt Cap304.1B
Novartis offers several cancer treatments, including therapies for multiple myeloma, positioning it as a competitor.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a growing oncology division with treatments that could compete against Oncopeptides' pipeline.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie, with its broad oncology portfolio, including therapies for hematologic cancers, competes in the same market as Oncopeptides.
Merck
MRK
Mkt Cap370.89B
Merck & Co.'s strong oncology pipeline, including treatments for various cancers, makes it a competitor.
Takeda Pharmaceutical
TAK
Mkt Cap58.92B
Takeda Pharmaceutical, with its acquisition of Shire, has strengthened its position in the oncology market, including treatments for multiple myeloma, competing with Oncopeptides.

About

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Ms. Sofia Heigis M.Sc.
Employees
80
Country
United States

Listings

MU
DE
OND.MU
STU
DE
OND.STU
ST
SE
ONCO.ST
LSE
GB
0RN4.LSE

0 Comments

Share your thoughts

FAQ

What is Oncopeptides AB (publ) stock price today?▼
The current price of ONPPF is $0.27 USD — it has decreased by -70.56% in the past 24 hours. Watch Oncopeptides AB (publ) stock price performance more closely on the chart.
What is Oncopeptides AB (publ) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Oncopeptides AB (publ) stocks are traded under the ticker ONPPF.
What is Oncopeptides AB (publ) revenue for the last year?▼
Oncopeptides AB (publ) revenue for the last year amounts to -195,034.9 USD.
What is Oncopeptides AB (publ) net income for the last year?▼
ONPPF net income for the last year is 887,311.29 USD.
How many employees does Oncopeptides AB (publ) have?▼
As of September 09, 2026, the company has 80 employees.
In which sector is Oncopeptides AB (publ) located?▼
Oncopeptides AB (publ) operates in the Health & Wellness sector.
When did Oncopeptides AB (publ) complete a stock split?▼
Oncopeptides AB (publ) has not had any recent stock splits.
Where is Oncopeptides AB (publ) headquartered?▼
Oncopeptides AB (publ) is headquartered in Stockholm, United States.